Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:52 PM
Ignite Modification Date:
2025-12-24 @ 2:52 PM
NCT ID:
NCT00978159
Eligibility Criteria:
Inclusion Criteria:
* at least moderate pain or discomfort (or both) centered in the upper abdomen as their predominant symptoms for 7 days before randomization; taking low dose aspirin (80-300 mg daily),and insignificant upper endoscopic finding. At least moderate pain or discomfort is defined if the HKDI was more than or equal to 16.
* H. Pylori: In patients with have successful eradication of H. pylori and had dyspepsia with HKDI \>=16 at the 6th week after eradication therapy can be recruited.In patients without H. pylori infection, they can be recruited immediately.
Exclusion Criteria:
* non-Chinese speaking
* significant endoscopic finding
* typical biliary colic
* predominant heartburn or symptoms of the irritable bowel syndrome
* a history of peptic ulcer or gastroesophageal reflux
* unintentional weight loss previous gastric or duodenal surgery
* thrombocytopenia
* renal failure with estimated creatinine clearance less than 10 ml/min
* active cancer
* known allergic to aspirin, famotidine or esomeprazole
* pregnancy, lactation, child-bearing potential in the absence of contraception
* planned co-prescription of nonsteroidal anti-inflammatory drugs
* corticosteroid, clopidogrel or anticoagulant
* anxiety neurosis, depression, psychosomatic disorder
* investigation for dyspepsia with endoscopy or barium series before aspirin therapy or disorders that might modify the absorption of study drugs
* ongoing treatment with a histamine H2-receptor antagonist, a prostaglandin, or a prokinetic drug during the 7 days before enrollment was not permitted, nor was treatment with a proton-pump inhibitor, or bismuth in the 30 days before enrollment
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00978159
Study Brief:
Protocol Section:
NCT00978159